Drugs / ADU-1805
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05856981 | Apr 2023 → May 2027 expected | clear cell renal carcinoma, colorectal cancer, endometrial cancer, metastatic neoplasm +2 | Sairopa B.V. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-02-13 | Sairopa B.V. | Regulatory Exelixis and Sairopa announce US FDA clears Investigational New Drug application for ADU-1805 in patients with advanced solid tumors - Sairopa sairopa.com ↗
Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the U.S. Food and Drug Administration (FDA) has cleared Sairopa’s Investigational New Drug (IND) Application to evaluate the safety and pharmacokinetics of ADU-1805 in adults with advanced solid tumors. |
| 2023-02-13 | Exelixis | Regulatory Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors exelixis.com ↗
Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the U.S. Food and Drug Administration (FDA) has cleared Sairopa’s Investigational New Drug (IND) Application to evaluate the safety and pharmacokinetics of ADU-1805 in adults with advanced solid tumors. |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADU-1805 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05856981 ↗ |
| Modality | Monoclonal antibody | “anti- SIRPα monoclonal antibody” NCT05856981 ↗ |
| Route | Intravenous | “Monotherapy dose escalation, IV, Q3W, multiple dose levels” NCT05856981 ↗ |